Aria Pharmaceuticals revealed promising results from the third preclinical study of TRX-1002, an idiopathic pulmonary fibrosis (IPF) treatment candidate, that showed a significant decrease in absolute lung weight, fibrosis score, and collagen and hydroxyproline levels.  

The findings, revealed in a press release, were presented at the 6th Annual Antifibrotic Drug Development Summit in Boston, Massachusetts.

“People suffering from IPF need new and novel treatments because while today’s treatments slow disease progression, they do not stop it and are associated with a high rate of discontinuation,” stated Martin Kolb, MD, PhD, director of the division of respirology at McMaster University. “The incidence and burden of IPF are increasing globally, so discovering and developing new treatments needs to be a priority.”


Continue Reading

The study results indicated that oral, once-daily TXR-1002 treatment at 10, 30, and 100 mg/kg significantly decreased absolute lung weight and hydroxyproline levels compared with the disease control group, while lung histopathology testing showed notably decreased fibrosis score and collagen levels similar to the nintedanib treatment group at 60 mg/kg. 

Read more about IPF treatment

To evaluate the safety and efficacy of the novel drug, the researchers assembled four groups of male Sprague Dawley rats treated with different doses of TRX-1002, a bleomycin-induced IPF disease control group, a placebo group, and a nintedanib treatment group. TRX-1002 was administered in a dose-response curve mode at 3, 10, 30, and 100 mg/kg at once per day dosing. 

In contrast to the previous two studies conducted by Aria Pharmaceuticals, the most recent one used a bleomycin-induced model in male Sprague Dawley rats instead of traditional mice whose airway anatomy is less complex. 

“We continue to see promising data for our IPF candidate TXR-1002, validating our efforts to advance this program toward IND-enabling studies,” noted Anjali Pandey, PhD, senior vice president of nonclinical R&D and chemistry at the company.  

Reference

Aria Pharmaceuticals presents positive in vivo data on lead idiopathic pulmonary fibrosis treatment candidate. News release. Aria Pharmaceuticals; November 14, 2022.